Introduction {#s1}
============

Strokes are considered to be a major cause of death and disability in the world ([@B18]). Nearly 87% of all stroke cases are triggered by ischemic stroke ([@B49]). Currently, the most effective agent and the only FDA-approved drug used for ischemic stroke treatment is recombinant tissue plasminogen activator. However, a large amount of stroke patients fail to respond to this drug, owing to its narrow therapeutic time window and a serious risk of hemorrhagic complications ([@B36]; [@B55]). A major challenge of thrombolytic treatment is ischemia/reperfusion (I/R) injury, which is considered as a main cause of brain injury and function destruction. Reperfusion after cerebral ischemia increases the risk of brain hemorrhage, while leading to neurovascular injury and producing excessive reactive oxygen species (ROS) which damage the blood-brain barrier ([@B1]). A number of studies have confirmed that the disruption of the BBB is a major cause of the pathogenesis of ischemic stroke ([@B7]).

The BBB consists mainly of endothelial cells, pericytes, astrocytes, neurons, and the basement membranes. The core components of the BBB are cerebral microvascular endothelial cells that are joined by tight junctions, thus restricting exogenous molecules into the brain. The pathological alterations of tight junctions---particularly occludin, claudin-5, and zonula occludens-1 (ZO-1)---significantly affect the BBB function during an ischemic stroke, especially barrier permeability ([@B41]; [@B26]; [@B43]). During I/R periods, excessive ROS is one of the main factors leading to the direct damage of brain neurons ([@B15]). ROS overproduction leads to the degradation of certain junctions and BBB disruption, which results in exogenous molecules entering into the brain through the BBB, leading to brain damage aggravation ([@B9]; [@B79]). Therefore, protection of the BBB by anti-oxidants has been regarded as a potential way to prevent reperfusion injury.

Besides the breakdown of the BBB, I/R can result in neurovascular injury and neuronal death ([@B32]). During a stroke, increased neuronal cell death may result from oxidative stress ([@B10]), and numerous studies have shown that ROS aggravates stroke severity and neurological damage ([@B35]; [@B11]; [@B12]). Although clinical trials have not got satisfactory results, neuroprotection is still a promising strategy for treatment of acute ischemic stroke ([@B47]). Thus, finding effective neuroprotection drugs to treat strokes is a benefit for stroke patients.

Traditional Chinese medicine (TCM) takes measures to intervene against the body\'s internal imbalance ([@B21]). Owing to the complex pathogenesis of ischemic strokes, the multifactorial effect of TCM and their active constituents play a critical role in the treatment of strokes. *Cistanche deserticola* Y. C. Ma, widespread in arid or semi-arid areas throughout Mongolia and Northwest China, has been a widely used TCM herb for the treatment of various diseases such as forgetfulness and depression for more than 1,000 years in China. Modern pharmacological studies indicated that the crude extracts from *C. deserticola* showed multiple pharmacological activities, such as enhancing learning and memory function, neuroprotection, enhancing immunity, antioxidant, anti-aging, and antifatigue effects ([@B34]; [@B64]; [@B37]). Chemical analysis of *C. deserticola* showed that its main constitutes include phenylethanoid glycosides, iridoid glycosides, polysaccharides and oligosaccharides ([@B29]). However, the active components of *C. deserticola* for brain protection are not very clear.

The neuroprotective property of *C. deserticola* implies its therapeutic potential in cognitive-related illness such as stroke and depression, as well as Alzheimer\'s disease ([@B66]). However, research on the impact of *C. deserticola* on strokes, including its active components and action mechanisms, is very limited. In the current work, we explored the protective effect of three extracts from *C. deserticola*, total glycosides (TGs, phenylethanoid glycosides, and other glycosides), polysaccharides (PSs), and oligosaccharides (OSs) on cerebral I/R injuries. Our findings may contribute to the accurate clinical application of *C. deserticola* and provide a candidate agent for ischemic stroke therapy.

Materials and Methods {#s2}
=====================

Chemicals and Reagents {#s2_1}
----------------------

The stems of *Cistanche deserticola* were purchased from Alashan, Inner Mongolia, and identified by one of the authors (P.-F. Tu). TGs, PSs, and OSs were prepared according to our previously reported method ([@B22]). Quantitative analysis of TGs was performed by high-performance liquid chromatography (HPLC) as previously described ([@B39]), and its chromatogram is shown in [**Figure 1**](#f1){ref-type="fig"}. The main components of TGs are echinacoside, tubuloside A, acteoside, isoacteoside, and 2\'-acetylacteoside; their contents are 163.05 mg/g, 4.125 mg/g, 41.66 mg/g, 22.655 mg/g, and 12.045 mg/g, respectively. The contents of PSs and OSs are 69.42% and 65.24%, respectively, as determined by HPLC and the phenol--sulfuric acid analysis, respectively ([@B81]; [@B57]).

![The HPLC chromatograms of the TGs **(A)** and standard references **(B)**. (a) echinacoside, (b) tubuloside A, (c) acteoside, (d) isoacteoside, (e) 2\'-acetylacteoside of TGs.](fphar-11-00236-g001){#f1}

The standard references of echinacoside (A0282), tubuloside A (A0942), acteoside (A0280), isoacteoside (A0281), and 2\'-acetylacteoside (A0943) were purchased from Chengdu Must Biotechnology (Sichuan, China). The purities of all standards are more than 98%. Nissl stain H&E kits were bought from Boster (Wuhan, China). Edaravone (T0407-1) was bought from Target Mol (Shanghai, China). Rabbit anti-rat MAP-2 (ab32454), Nrf-2 (ab31163), PDGFRβ (ab32570), Keap-1 (ab66620), and mouse anti-rat CD31 (ab24590) were purchased from Abcam Inc (Cambridge, MA, USA). Rabbit anti-rat Claudin5 (BS1069), ZO-1 (BS9802M), and Occludin (BS72035) were bought from Bioworld Technology (Nanjing, China). Cell Signaling Technology Inc. (Boston, MA, USA) was the source of rabbit anti-rat Synapsin-1 (SYN,5297T), PSD95 (3450T), α-Smooth Muscle Actin (α-SMA,19245T). GAPDH (HRP-60004) was purchased from Proteintech Group, Inc. (Chicago, USA). Secondary antibodies were supplied by Zhongshan Golden Bridge Biotechnology (Beijing, China). Hoechst 33258 was obtained from Beyotime (Jiangsu, China).

Animals {#s2_2}
-------

Sprague-Dawley rats (male, weighing 250--300g) were obtained from Vital River Laboratory Animal Technology (Beijing, China) and housed in an airconditioned room kept on a 12 h light/dark cycle. All animal experiments were performed in accordance with the animal research ARRIVE guidelines ([@B33]; [@B45]), and approved by the Institutional Animal Care and Use Committee of Peking University Health Science Center (LA2019123).

Animal Experimental Protocols {#s2_3}
-----------------------------

The rats were subjected to MCAO/R, as previously described ([@B67]). Briefly, the left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed, and a 3-0 nylon monofilament suture was inserted from the ECA into the ICA until reaching the middle cerebral artery (MCA). After 1.5 h of MCA occlusion, reperfusion was simulated by removing the filament. During the surgical procedure, the body temperature of all rats was maintained at 37.0°C.

Drug Administration {#s2_4}
-------------------

The rats were randomly separated into six groups using the SPSS software version 22.0 as described ([@B30]): normal group (NOR); model group (MOD); edaeavone group (positive drug, 6 mL/kg, EDI); TGs group (280 mg/kg, TGs); PSs group (280 mg/kg, PSs), and OSs group (280 mg/kg, OSs). TGs, PSs, and OSs were administrated ig once a day after MCAO/R for 14 days. The NOR and MOD groups were treated with normal saline. The animal numbers are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Number of animals for different experimental groups and various parameters at 14 d after administration.

  Parameters          NOR   MOD   EDI   TGs   PSs   OSs   Total
  ------------------- ----- ----- ----- ----- ----- ----- -------
  Weight, mNSS        18    18    18    18    18    18    108
  TTC                 8     8     8     8     8     8     48
  H&E,Nissl stain     5     5     5     5     5     5     30
  Immunofluorescent   5     5     5     5     5     5     30
  Total               36    36    36    36    36    36    216

Measurement of Weight and Modified Neurological Deficit Scores (mNSS) {#s2_5}
---------------------------------------------------------------------

Body weight was monitored on the 14th day using an ADVENTURE™ Digital Scale (OHAUS, New Jersey, USA). The mNSS was assessed according to the method described by FJ Wang ([@B67]), with minor revisions.

2, 3, 5-Triphenyltetrazolium Chloride (TTC) Staining {#s2_6}
----------------------------------------------------

Infarct volume was measured as described previously ([@B65]). In brief, the brains were sectioned into seven equally spaced coronal blocks (2 mm). These sections were stained with 2% TTC (Coolaber, Beijing, China) at 37°C for 15 min. Infarct volume (%) = (ipsilateral ischemic hemisphere volume−contralateral ischemic hemisphere volume)/contralateral ischemic hemisphere volume × 100.

Nissl and H&E Staining {#s2_7}
----------------------

The rats were deeply anesthetized, and the whole brain was then rapidly removed from the skull and fixed using 4% paraformaldehyde and embedded in paraffin wax and sectioned into slice of 7 µm thickness. The sections were stained with Nissl and H&E. In this study, six random 200 × 200 µm fields were captured in each tissue specimen with a light microscope. The number of Nissl\'s bodies was counted with IPP software version 6.0 (Media Cybernetics, Bethesda, USA).

Evans Blue Assay {#s2_8}
----------------

Rats were injected with 2% EB (Coolaber Science & Technology Co., LTD) after MCAO/R. Two hours later, the rats were anesthetized and the whole brain was then rapidly removed and homogenized in acetone. The supernatants were analyzed at 620 nm by an 800 TS absorbance reader (BioTek, USA).

Measurement of the Activities of Catalase (CAT), Superoxide Dismutase (SOD), Malondialdehyde (MDA), and Glutathione Peroxidase (GSH-Px) {#s2_9}
---------------------------------------------------------------------------------------------------------------------------------------

All serum samples were centrifuged at 4,000 × rpm for 15 min at 4°C, and then analyzed to detect the activities of MDA, CAT, SOD, and GSH-Px following the manufacturer\'s instructions (Jiangsu Meimian industrial Co., Ltd, China).

Western Blotting Analysis {#s2_10}
-------------------------

Brain tissues (100 mg) collected from each rat were homogenized and lysed in RIPA lysis buffer, and then analyzed to detect the protein concentration using a BCA kit (Beijing TransGen Biotech Co., Ltd.). Tissue total proteins were loaded on 10% SDS-PAGE gels and transferred onto a nitrocellulose membrane. The membrane was blocked using 5% skim milk, then incubated overnight with primary antibodies at 4°C. The membrane was then incubated with a secondary antibody. Western blot analysis was analyzed using Kodak Digital Imaging System (5200 Multi, Tanon, China).

Immunofluorescent Analysis {#s2_11}
--------------------------

Immunofluorescence staining for CD31, α-SMA, ZO-1, claudin5, occludin, PDGFRβ, SYN, PSD95, MAP-2, Nrf-2 and Keap-1 were performed. Primary antibodies against Nrf-2, CD31, α-SMA, ZO-1, claudin5, occludin, PDGFRβ, SYN, PSD95, MAP-2 and Keap-1 were diluted to 1:200 and 1:100, respectively. The secondary antibodys of Alexa Flur 488 mouse anti-rabbit IgG and rhodamine (TRITC) goat anti-rabbit IgG were both diluted to 1:200. The nucleuses were stained by Hoechst 33258. Images were captured using Vectra^®^ Polaris™ Automated Quantitative Pathology Imaging System (PerkinElmer, USA). The protein expression was analyzed using IPP software version 6.0.

Statistical Analysis {#s2_12}
--------------------

All data were described as mean ± SD. SPSS software version 22.0 was performed for statistical analysis. One-way ANOVA was used when comparing different groups. *P* \< 0.05 was considered to be statistical difference.

Results {#s3}
=======

TGs Increase Body Weight and Reduces Brain Damages in MCAO/R Rats {#s3_1}
-----------------------------------------------------------------

After 14 days of cure with TGs, PSs, Oss, and EDI, the body weights, neurological deficits and infarct volumes of I/R rats were evaluated. The results showed that the body weights in the MOD group were greatly decreased, while the decreased weights in TGs, PSs and EDI groups were obviously increased ([**Figure 2A**](#f2){ref-type="fig"}). Neurological deficit scores were substantially lowered by EDI and TGs ([**Figure 2B**](#f2){ref-type="fig"}). The brain slices in NOR group rats were deep red and there were no infarctions, while the rats of the MOD group showed a large ipsilateral cerebral infarction. After TGs treatment, the infarct volumes were significantly reduced ([**Figures 2C, D**](#f2){ref-type="fig"}). The PSs and OSs treatment showed no obvious effect on the above indexes. The above data showed that TGs could markedly alleviate the I/R-induced cerebral injury, but PSs and OSs could not.

![TGs reduce the brain damage induced by transient focal cerebral ischemia. **(A)** TGs increase weight in the MCAO/R rats. **(B)** TGs decrease neurological deficit scores at 14 d post-MCAO/R. **(C, D)** Representative photographs of TTC-stained coronal brain sections show viable (red) and dead (white) tissues; TTC staining shows that the cerebral infarction areas in the TGs group are significantly smaller than those in the model group. \**P* \< 0.05 vs NOR. ^\#^ *P* \< 0.05 vs MOD.](fphar-11-00236-g002){#f2}

TGs Ameliorate Histopathological Damage in MCAO/R Rats {#s3_2}
------------------------------------------------------

In order to determine some of the effects of TGs, PSs, and OSs treatment on histopathological damages, H&E staining was done to reveal pathological damage. The histomorphological structures of brains in the NOR group were arranged regularly. The morphology changes in the TGs groups were slighter than those in the MOD group. However, the PSs and OSs treatment groups showed no significant amelioration of the morphology changes ([**Figure 3**](#f3){ref-type="fig"}).

![TGs ameliorate histopathological damage in MCAO/R rats. HE staining of coronal sections in the penumbra of ischemic areas of NOR, MOD, EDI, TGs, PSs, and OSs groups at 14 d after I/R. The cell morphology in the MOD group is shrinkage, nuclear pyknosis, and vacuolization, while the cells in the TGs group are relatively normal and show less damage, compared with those in the MOD group. **(A--F)** are NOR, MOD, EDI, TGs, PSs, and OSs groups, respectively. Scale bar = 100 µm.](fphar-11-00236-g003){#f3}

TGs Attenuate Neuronal Injury After I/R-Induced Rats {#s3_3}
----------------------------------------------------

Nissl staining showed the histopathological changes of neurons in the penumbra of ischemic area. As shown in [**Figure 4**](#f4){ref-type="fig"}, the normal neurons had a clear nucleolus and intact structure. In the MOD group, the neurons had enlarged intercellular spaces. The nissl bodies were disappeared, shrunken and deep stained. However, these changes were rarely observed in the EDI, TGs, and PSs groups. These results illustrated that TGs and PSs could significantly attenuate ischemia/reperfusion-induced neuronal injury.

![TGs attenuate neuronal injury after I/R-treated rats. **(A)** Nissl staining in the penumbra of ischemic area of I/R rats. Normal neurons have normal morphology with clear nucleolus, abundant cytoplasm, and intact structure (red arrow). Abnormal neurons are shrunken and deep stained (yellow arrow), while a greater increase of intact cells is evident in the TGs group compared with the MOD group. a--f are NOR, MOD, EDI, TGs, PSs and OSs groups, respectively. **(B)** Quantitative analysis of intact cells in penumbra of ischemic area at 14 days after treatment. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD.](fphar-11-00236-g004){#f4}

TGs Attenuate BBB Disruption After I/R-Treated Rats {#s3_4}
---------------------------------------------------

Evans blue assay is a classical method for researching the change of BBB permeability. The experiment results showed that increased Evans blue was observed in the MOD group, while there was significantly decreased Evans blue in the TGs and EDI treated rats. Moreover, there was no significant difference between PSs and OSs therapy groups ([**Figure 5**](#f5){ref-type="fig"}). These results suggested that TGs could significantly attenuate BBB disruption.

![TGs attenuate BBB disruption after I/R injury. **(A)** Representative pictures of Evans blue extravasation. a--f are NOR, MOD, EDI, TGs, PSs, and OSs groups, respectively. **(B)** Quantitative analysis of Evans blue extravasation from brain extracts at 14 days after treatment. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD.](fphar-11-00236-g005){#f5}

TGs Promote Angiogenesis in I/R Injured Rats {#s3_5}
--------------------------------------------

More recent studies show that angiogenesis plays a critical role in neurological functional recovery and prognostic outcome after acute ischemic stroke ([@B77]). To evaluate effects of TGs, PSs, and OSs on angiogenesis, the CD31 and α-SMA were used to quantify the capillary numbers. Immunofluorescence staining showed that the MOD group caused a remarkable decrease in the expressions of CD31 ([**Figures 6A**, **B**](#f6){ref-type="fig"}) and α-SMA ([**Figures 6C**, **D**](#f6){ref-type="fig"}) in the penumbra of ischemic areas of I/R rats, in comparison with the normal rats. This result illustrated that I/R could cause the vascular damage in the cortex penumbra of ischemic hemispheres. However, the TGs and EDI treatment remarkably increased capillary density, angiogenesis, and arteriogenesis as indicated by increased expressions of CD31 and α-SMA. These results suggest that TGs could promote angiogenesis in the ischemic penumbra of I/R rats, but the PSs and OSs could not.

![TGs promote neovascularization in rats with cerebral I/R. Representative images obtained from the cortex penumbra of ischemic hemispheres. **(A, C)** Representative immunoﬂuorescence images of CD31 and α-SMA in the I/R rats after treatment with TGs, PSs and OSs for 14 days, respectively. a--f are NOR, MOD, EDI, TGs, PSs, and OSs groups, respectively. **(B, D)** The bar graphs show the analysis of positive immunostaining of CD31 and α-SAM in the I/R rats at 14 days after treatment. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD. Scale bar in all panels = 100 μm.](fphar-11-00236-g006){#f6}

TGs Increase Expression of Tight Junction Proteins in I/R Injured Rats {#s3_6}
----------------------------------------------------------------------

BBB disruption can elevate brain water content and tissue swelling, leading to brain injury. Tight junction proteins are important structural components of the BBB ([@B62]; [@B31]). To test whether TGs, PSs, and OSs treatment after stroke might influence BBB integrity, the expressions of ZO-1, claudin-5, and occludin were performed by immunoﬂuorescence analysis. The results indicated that the expressions of claudin-5, occludin, and ZO-1 were visibly decreased in the MOD group. However, they were substantially increased after 14 days of TGs administration. PSs and OSs groups showed no significant changes in these protein expressions ([**Figure 7**](#f7){ref-type="fig"}). These data indicated that the TGs can regulate tight junction protein expressions and probably maintain BBB integrity after I/R injury.

![TGs increase expression of tight junction proteins in MCAO/R rats. Representative images obtained from the cortex penumbra of ischemic hemispheres. **(A, C, E)** Protein expression levels of ZO-1, claudin5, and occludin were measured by immunoﬂuorescence, respectively. **(B, D, F)** Statistical analysis of the numbers of ZO-1, claudin5, and occludin positive cells, respectively. a--f are NOR, MOD, EDI, TGs, PSs and OSs groups, respectively. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD. Scale bar = 50 μm.](fphar-11-00236-g007){#f7}

TGs Increase Pericyte Coverage on Capillaries in I/R Injured Rats {#s3_7}
-----------------------------------------------------------------

Pericyte coverage on capillaries plays a critical role in maintaining BBB integrity ([@B2]; [@B14]). Thus, we tested whether pericyte coverage could be increased by TGs, PSs, and OSs treatment. Immunoﬂuorescence intensity analysis results showed that both PDGFRβ and CD31 expressions were dramatically decreased in the MOD group. Administration of TGs to the I/R rats significantly recovered or even increased the expression intensities of the PDGFRβ and CD31, but no difference was observed in the PSs and OSs treatment groups ([**Figure 8**](#f8){ref-type="fig"}). Thus, treatment of TGs could significantly increase pericyte coverage. These findings further confirmed that TGs can maintain the integrity of BBB after I/R.

![TGs increases pericyte coverage on capillaries in I/R injury rats. Representative images obtained from the ischemic penumbra of cortex. **(A)** Representative immunoﬂuorescence images of PDGFRβ (green) and CD31 (red) staining in the MCAO/R rats at 14 days after TGs, PSs and OSs treatment. a--f are NOR, MOD, EDI, TGs, PSs and OSs groups, respectively. **(B)** Ratio of CD31-positive cell numbers to the PDGFRβ-positive cell numbers in each tissue. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD. Scale bar in all panels = 20 μm.](fphar-11-00236-g008){#f8}

TGs Promote Neural Remodeling in I/R Injured Rats {#s3_8}
-------------------------------------------------

According to numerous studies, neurogenesis after a stroke can significantly improve functional recovery ([@B24]; [@B83]). Synaptophysin (SYN), postsynaptic density 95 (PSD-95) proteins and microtubule-associated protein 2 (MAP-2) were used as markers to examine neuronal plasticity in the ischemic penumbra of the cortex. In order to assess the effects of TGs, PSs, and OSs treatment on neurogenesis in I/R injured rats, the immunoﬂuorescence and western blot for SYN, PSD95 and MAP-2 expressions were performed. As shown in [**Figures 9**](#f9){ref-type="fig"} and [**10**](#f10){ref-type="fig"}, the SYN, PSD95 and MAP-2 expression levels in I/R rats after 14 days reperfusion decreased in comparison with the NOR rats, while the TGs and PSs cure could significantly up-regulate their expression levels. The OSs group had no significant change compared with the MOD group. The data indicated that the TGs and PSs cure was able to dramatically promote neural remodeling after I/R injury.

![TGs promote neural remodeling in I/R injury rats. Representative images obtained from the cortex penumbra of ischemic hemispheres. **(A, C, E)** Representative immunoﬂuorescence images of MAP-2, PSD95 and SYN in the MCAO/R rats at 14 days after TGs, PSs and OSs treatment. **(B, D, F)** Statistical analysis of the numbers of MAP-2, PSD95 and SYN positive cells, respectively. a--f are NOR, MOD, EDI, TGs, PSs and OSs groups, respectively. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD. Scale bar in all panels = 50 μm.](fphar-11-00236-g009){#f9}

![TGs promote the expressions of MAP-2, PSD95, SYN and Nrf-2 and reduce the expression of Keap-1 in I/R-treated rats. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD.](fphar-11-00236-g010){#f10}

TGs Alter Nrf-2 and Keap-1 Expressions in I/R Injured Rats {#s3_9}
----------------------------------------------------------

Oxidative stress is a main pathogenic mechanism in I/R injury ([@B72]; [@B76]). The studies verified that Nrf-2 is a master regulator of antioxidative responses ([@B63]). To investigate Nrf-2 and Keap-1 mediated oxidative responses after I/R injury, we evaluated the cytoplasmic expression as well as nuclear translocation of Keap-1. Meanwhile, the expression of Nrf-2 in I/R injured rats brain tissues was also assayed ([**Figures 10**](#f10){ref-type="fig"} and [**11**](#f11){ref-type="fig"}). According to the immunofluorescence analysis, Nrf-2 was found to be mainly located at the cytoplasm in the NOR group. In the TGs group, the expression of Nrf-2 in cytoplasmic localization was downregulated, but upregulated in the nucleus, and a decreased Keap-1 expression was also observed. The data showed that the brain protection of TGs could be associated with the modulation of Nrf-2 and Keap-1.

![TGs significantly decrease the expression of Keap-1 and facilitate the nuclear translocation of Nrf-2. Representative images obtained from the cortex penumbraof ischemic hemispheres. **(A)** Keap-1 dependent Nrf-2 nuclear translocation was observed in I/R rats brain tissue. **(C)** Keap1 degradation after TGs treatment to I/R rats braintissue. The analysis was carried out using immunofluorescence staining. af are NOR, MOD, EDI, TGs, PSs and OSs groups, respectively. **(B**, **D)** Bar graphs show aquantification of the nucleus/cytoplasmic ratio of Nrf-2 and the expression of Keap-1. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD. Scale bar = 100 mm.](fphar-11-00236-g011){#f11}

TGs Attenuate Brain Tissue Oxidative Stress in I/R Injured Rats {#s3_10}
---------------------------------------------------------------

In order to confirm the antioxidative effects of TGs, the activities of SOD, CAT, GSH-Px and MDA were evaluated in I/R injured rats. In [**Figure 12**](#f12){ref-type="fig"}, the content of MDA was markedly increased in the MOD group, and at the same time the activities of SOD, CAT, and GSH-Px were decreased, compared to the normal rats. Conversely, TGs treatment led to a significant decrease in the content of MDA and increase in the activities of SOD, CAT and GSH-Px. These results further confirmed the antioxidation activity of TGs.

![TGs elevate the levels of SOD, CAT and GSH-Px and reduces the level of MDA in I/R-treated rats. The content of MDA increases in the brain tissue after I/Rinjury, along with the activities of SOD, CAT, and GSH-Px decrease. TGs treatment reverses these injury-induced changes. \**P* \< 0.05 vs NOR, ^\#^ *P* \< 0.05 vs MOD.](fphar-11-00236-g012){#f12}

Discussion {#s4}
==========

Many studies suggest that the TCM *C. deserticola* has extensive biological activities, e.g. enhancing the ability to learn, memory, and immunity ([@B17]; [@B29]; [@B66]; [@B69]). However, the active components of *C. deserticola* for neuroprotection remain unclear. The current work aims to screen the active components from *C. deserticola* against ischemic stroke on the MCAO/R model. Three extracts from *C. deserticola* (TGs, PSs, and OSs) were used to evaluate their effects on MCAO/R rats, as well as possible mechanisms.

Stroke is a common acute cerebrovascular disease. Epidemiological studies show that stroke is more common in men than in women ([@B56]; [@B25]). Thus, in our experiment, male rats were adopted for the tests. Our results proved that I/R induction accelerated oxidative stress and infarct volume, breaking the BBB and leading to nerve and cerebrovascular injury. After screening, TGs were found to decrease infarct volume and promote neural remodeling and angiogenesis. Moreover, TGs were observed to maintain BBB integrity after I/R injury. On the contrary, PSs and OSs bring no significant alleviation to I/R injury. Thus, TGs are considered the major active fraction of *C. deserticola* for neuroprotection, potentially through promoting neural remodeling, angiogenesis and BBB integrity *via* activating Nrf-2/Keap-1 pathway.

Mounting evidence indicates that establishment of effective collateral circulation is significantly important for avoiding the formation of infarction and ischemic penumbra, and is a critical treatment at an early stage of ischemic stroke ([@B20]; [@B27]). The proliferation of vascular endothelial cells and smooth muscle cells after ischemic infarction determines the establishment of collateral circulation. However, the ischemia models have a common phenomenon---that is, oxidative stress widely existed in the brain microvasculature. Study data have displayed that a large number of antioxidants can disturb the function of the BBB and the properties of angiogenesis ([@B46]). CD31 and α-SMA are the markers of vascular endothelial cells as well as smooth muscle cells, respectively ([@B53]). To investigate the effect on the above-mentioned cell proliferation of the extracts from *C. deserticola*, we examined the expressions of CD31 and α-SMA in the cerebral ischemic penumbra homogenate. Our data showed that TGs strikingly enhanced the expressions of CD31 and α-SMA. However, there was no significant differences for PSs and OSs groups. Therefore, we deduced that TGs may reduce brain damage by promoting angiogenesis *via* increasing the expressions of CD31 and α-SMA, whereas PSs and OSs provided no such protection from brain damage. These results further confirmed that only TGs could prevent cerebral I/R injury.

Ischemic stroke can be thought as the result of cerebral ischemia caused by impairment in the neuronal plasticity or remodeling of brain areas. The majority of stroke patients suffer neurological deficits. Activating neurogenesis is a promising strategy for stroke patients to improve their neurological functions ([@B13]). Neurogenesis directly participates in neurological function recovery after brain I/R injury ([@B83]). Previous research shows that TGs can improve the survival rate of hippocampal pyramidal cells and induce neurogenesis ([@B40]). Oxidative stress causes the loss of neurons during lots of diseases, such as Parkinson, stroke, and so on ([@B19]; [@B58]). Nrf-2 transcribes lots of genes related to neuro-protection in their promoter region, mainly including SOD, MDA, CAT, and γ-glutamyl cysteine ligases, etc ([@B54]). SYN, PSD-95, and MAP-2 proteins, which are associated closely with synaptic formation and neurotransmission, can be considered as markers of research neuronal plasticity in the ischemic penumbra region. After studying, we found that the cure with TGs could significantly increase the expressions of PSD95, SYN, and MAP-2, indicating that the cerebral protection of TGs was correlated with the enhanced neuronal plasticity during I/R. However, it\'s a pity that there is no obvious difference for PSs as well as OSs groups. These results indicated that TGs could enhance neuroplasticity after cerebral I/R injury.

Imaging research into stroke patients showed that BBB dysfunction can be thought as a striking attribute of the peri-ischemic brain ([@B3]). The TJs, which are composed of cytoplasmic proteins, transmembrane proteins, and junction adhesion molecules between capillary endothelial cells, are very important in maintaining BBB integrity ([@B73]). Among them, ZO-1, claudin-5, and occludin are the most important proteins in TJs. Mounting evidence indicates that the increased permeability of BBB induced by ischemia generally correlates with the alterations of ZO-1, claudin-5, and occludin ([@B6]; [@B50]; [@B75]; [@B42]). In this work, the results demonstrated that although TGs could significantly increase the expressions of ZO-1, claudin-5, and occludin proteins in MCAO-induced brain tissues, neither PSs nor OSs did. The BBB consists of cerebral endothelial cells and is closely associated with pericytes ([@B48]). Pericytes are vital to BBB integrity ([@B4]). Ischemic stroke triggers pericytes death and detachment from brain endothelial cells in the acute phase, thus destabilizing the microvasculature and altering BBB properties ([@B78]). Our data showed that TGs could increase pericyte coverage on capillaries and increase the expression levels of ZO-1, claudin-5 and occludin. These phenomena proved that TGs could effectively protect BBB integrity after cerebral I/R injury. In summary, TGs may attenuate cerebral injury in multiple ways, such as promoting angiogenesis, improving neuronal plasticity, and maintaining the integrity of the BBB.

We then investigated the signaling pathway to explore the mechanism underlying the TGs brain protection. The process of I/R injury is multifactorial, and thus numerous mechanisms are involved in the pathogenesis. Oxidative stress is a fundamental risk factor contributing to I/R-induced brain injury ([@B60]), such as BBB structure damage, vascular endothelial dysfunction, and aggravation of ischemic neuronal injury ([@B70]; [@B5]; [@B52]). Thus, oxidative stress has become an attractive therapeutic target in I/R-induced brain injury. Phase 2 enzymes, which are mediated by nuclear factor E2-related factor-2 (Nrf-2), have been considered as an important means by which neurons protect themselves against oxidative stress ([@B61]; [@B72]). Mounting evidences indicate that activation of Nrf-2 during I/R is a potential therapeutic target for neuroprotection ([@B16]; [@B80]). Nrf-2, as an important regulator of endogenous antioxidant defense, mediates the level of heme oxygenase 1 (HO-1) and other antioxidant enzymes, such as NAD(P)H quinone oxidoreductase 1 (NQO1), SOD, CAT, GSH, and MDA ([@B59]; [@B15]). Moreover, Nrf-2 plays an important regulator role in angiogenesis. The present study shows that Nrf-2 can be significantly enhanced and activated in the process of vascular development ([@B68]).

As previously described ([@B29]), TGs contain lots of bioactive compounds, for example echinacoside, tubuloside A, acteoside, isoacteoside and 2\'-acetylacteoside, and some of them showed neuroprotective functions after cerebral I/R injury ([@B51]). Echinacoside has lots of pharmacological effects, such as antioxidation, anti-senescence, neuroprotection, anti-inflammation, promotion of cicatrization, hepatoprotection, promotion of bone formation and anti-tumor activities ([@B74]; [@B38]; [@B82]; [@B28]; [@B71]). Recently, echinacoside has been identified as a potent antioxidant in the central nervous system ([@B44]). Echinacoside can cut down MDA content and improve the activities of SOD and GSH-Px in ischemia brain injury, and molecular docking analysis displayed that echinacoside may bind to Keap-1, leading to the Nrf-2 nuclear translocation ([@B38]). The study of Xia showed that acteoside could decrease the infarct volume and brain water content to improve neurological deficits in MCAO/R rats through mitigating oxidative stress ([@B69]). Other studies have demonstrated that isoacteoside could increase the activities of cellular antioxidant enzymes, SOD and CAT in H~2~O~2~-treated V79-4 cells ([@B8]). Based on the above reports of the active compounds contained in TGs, it is possible to deduce that TGs could protect against ischemic stroke *via* the antioxidation pathways.

Li reported on the neuroprotective effects of phenylethanoid glycosides (PhGs) on H~2~O~2~-induced apoptosis on PC12 cells *via* the Nrf2/ARE pathway ([@B38]). These PhGs significantly suppressed by triggering Nrf2 nuclear translocation and increasing expressions of HO-1, NQO1, glutamate cysteine ligase-catalytic subunit (GCLC), and glutamate-cysteine ligase modifier subunit (GCLM) ([@B38]; [@B23]). Therefore, these findings suggest that the Nrf-2/ARE pathway plays a crucial role in PhGs-mediated protective effects on neuronal cells. Similarly, in this study, we found that TGs could decrease the level of MDA and increase the levels of SOD, CAT, and GSH-Px in the I/R rats. Meanwhile, TGs could upregulate the Nrf2 expression in the nucleus, downregulate the corresponding expression in the cytoplasm, and significantly decrease the Keap-1 expression. Therefore, the Nrf-2/Keap-1 pathway may be involved in TGs-mediated neuroprotective effects. Further validation of this pathway would be performed *in vitro* cell culture with oxygen-glucose deprivation/reoxygenation injury models in the future. Moreover, *C. deserticola* extracts were administrated in our study for 14 days continuously. Since adult neurogenesis would affect the interpretation of neuroprotective effects during 14 days reperfusion, neurogenesis cannot be excluded in our current experiment design in exploring the neuroprotective effect of CTs. This is the limitation of our research.

In conclusion, it is the TGs from *C. deserticola* that can enhance angiogenesis and neurogenesis as well as maintain the integrity of the BBB in I/R injury rats, but not the PSs and OSs. The effects could be mediated by the activation of the Nrf-2/Keap-1 pathway.
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